Wells Fargo
RAPT

Wells Fargo’s RAPT Therapeutics RAPT Stock Holding History

Wells Fargo’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,229
Closed -$9.83K – 7339
2025
Q2 		$9.83K Sell
1,229
-1,441
-54% -$11K ﹤0.01% 5955
2025
Q1 		$26.1K Sell
2,670
-556
-17% -$5.47K ﹤0.01% 5617
2024
Q4 		$40.8K Buy
3,226
+542
+20% +$6.88K ﹤0.01% 5558
2024
Q3 		$43.2K Buy
2,684
+698
+35% +$14.1K ﹤0.01% 5400
2024
Q2 		$48.5K Sell
1,986
-425
-18% -$19.6K ﹤0.01% 5305
2024
Q1 		$173K Buy
2,411
+850
+54% +$118K ﹤0.01% 4557
2023
Q4 		$310K Sell
1,561
-1,972
-56% -$244K ﹤0.01% 4190
2023
Q3 		$470K Sell
3,533
-1,176
-25% -$192K ﹤0.01% 3827
2023
Q2 		$704K Sell
4,709
-159
-3% -$24.8K ﹤0.01% 3708
2023
Q1 		$715K Buy
+4,868
New +$985K ﹤0.01% 3609
2022
Q4 		– Sell
-96
Closed -$19K – 7668
2022
Q3 		$19K Buy
96
+25
+35% +$4.73K ﹤0.01% 5432
2022
Q2 		$10K Sell
71
-719
-91% -$95.8K ﹤0.01% 5760
2022
Q1 		$139K Sell
790
-876
-53% -$165K ﹤0.01% 5165
2021
Q4 		$489K Buy
1,666
+1,631
+4,660% +$436K ﹤0.01% 4682
2021
Q3 		$9K Sell
35
-21
-38% -$5.55K ﹤0.01% 6241
2021
Q2 		$14K Sell
56
-276
-83% -$51.6K ﹤0.01% 6040
2021
Q1 		$58K Sell
332
-3,446
-91% -$568K ﹤0.01% 5747
2020
Q4 		$597K Sell
3,778
-2,469
-40% -$537K ﹤0.01% 4395
2020
Q3 		$1.61M Buy
6,247
+948
+18% +$210K ﹤0.01% 3489
2020
Q2 		$1.23M Buy
5,299
+3,629
+217% +$561K ﹤0.01% 3645
2020
Q1 		$284K Buy
1,670
+464
+38% +$106K ﹤0.01% 4449
2019
Q4 		$266K Buy
+1,206
New +$222K ﹤0.01% 4796

Other funds holding RAPT

MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BCM
Boone Capital Management Atlanta, Georgia $326M AUM 86.31% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Wells Fargo's RAPT Position: Q3 2025 in Review

Wells Fargo sold out of RAPT Therapeutics (RAPT) in Q3 2025, closing a stake of 1,229 shares — an estimated $9.83K sold.

Wells Fargo first reported a position in RAPT in Q4 2019 and held it in 22 quarters. The position peaked at $1.61M in Q3 2020. 65 funds tracked by Wall St. Rank hold RAPT as of Q3 2025.

  • Wells Fargo reported no remaining RAPT Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Wells Fargo sold 1,229 RAPT Therapeutics shares in Q3 2025, an estimated $9.83K.
  • Wells Fargo first reported a position in RAPT Therapeutics in Q4 2019 and held it in 22 quarters.
  • Wells Fargo's RAPT Therapeutics position peaked at $1.61M in Q3 2020.
  • 65 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q3 2025.

Based on Wells Fargo's 13F filing for Q3 2025, filed 13 Nov 2025.